# Clinical Course After Transcatheter Aortic Valve Replacement for Takayasu Arteritis–Related Aortic Stenosis and Regurgitation

## TL;DR

This paper examines the long-term outcomes of TAVR in patients with a rare blood vessel disease, showing it can be effective if the disease is well-controlled.

## Contribution

The study provides long-term clinical outcomes of TAVR in high-risk patients with TAK-related aortic valve disease.

## Key findings

- TAVR was performed without major complications in three patients with TAK.
- One patient relapsed and died 7 years post-TAVR due to disease-related complications.
- TAVR may offer acceptable long-term outcomes if TAK activity is suppressed.

## Abstract

Takayasu arteritis (TAK) is chronic, large-vessel vasculitis that frequently involves the aorta and its major branches, often leading to aortic valve disease. Recently, transcatheter aortic valve replacement (TAVR) has emerged as a less invasive alternative for patients with TAK-induced aortic stenosis who are at high risk for conventional surgical aortic valve procedures. However, long-term data remain limited. We report the clinical courses of 3 patients with TAK who underwent TAVR for aortic stenosis and regurgitation. No major complications were observed during the procedure or hospital stay. The mean follow-up duration after TAVR was 5.7 years. During follow-up, 1 patient experienced a relapse of TAK that led to low cerebral perfusion, heart failure, and subsequent death 7 years after TAVR. Our observations suggest that TAVR may yield acceptable long-term outcomes for high-risk patients with TAK if disease activity can be suppressed, thus preventing heart failure or cerebrovascular events.